NCT06678620View on ClinicalTrials.gov

Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

PHASE2RecruitingINTERVENTIONAL
Enrollment

992

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 31, 2025

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

Reinovax PCV24 formulation 1

One dose of Reinovax PCV24 formulation 1（0.5mL）

BIOLOGICAL

Reinovax PCV24 formulation 2

One dose of Reinovax PCV24 formulation 1（0.5mL）

BIOLOGICAL

Reinovax PCV24 formulation 3

One dose of Reinovax PCV24 formulation 1（0.5mL）

BIOLOGICAL

PPSV23

One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.

Trial Locations (2)

Unknown

RECRUITING

Pizhou Center for Disease Control and Prevention, Pizhou

RECRUITING

Xuzhou Center for Disease Control and Prevention, Xuzhou

All Listed Sponsors
lead

Shanghai Reinovax Biologics Co.,LTD

INDUSTRY